IP management@universities 2014Best practices: Univ-Ind collaborations

Jo Bury, managing director VIB

Istanbul, October 30th-31st, 2014

Policy factors impacting innovation: The case of FlandersJo Bury, managing director VIB

Flanders anno 1994

• well established support for R&D• good (life) science• stars of worldclass

Flanders anno 1994

• well established support for R&D• good (life) science• stars of worldclass• Innogenetics – Plant Genetic Systems

How can we do better?

SWOT analysis Flanders 1994

• S: - strong science base (champions)• W: - no structural funding

- brain drain- no tech transfer

• O: - develop an attraction pole of excellence- build a knowledge economy

• T: - loose leading position

Benchmarks

• Max Planck Society• MRC UK• Karolinska Institutet• Cold Spring Harbor Labs• Salk Institute• HHMI

Preliminary conclusions

• Focus on excellence• PI vs Dir as DMU• Combine strenghts• Build critical mass• Build a tech transfer pipeline• Develop a biotech cluster

Business plan

• build a new institute from scratcho attract the champions

↕• reunite the champions in 1 SRC

o multisiteo stringent selection

Business plan (2)

• thematic focus:o GE: molecular mechanism of life

• high level of ambition:o top 10% WW

• continuous improvement:o selection / continuation based on excellence

• institution:o not another granting body

Business plan (3)

• long term financial commitment:o significant (30-50%)o 22 M€/yearo 5 yearso renewable (if excellent)

• stringent selection of university departments:o 9/100

• independent structure (SRC):o board of directorso own facilities (TTO)

Reduction to practice

• Minister-President:o visionary (long term view)o right combination of powerso April 1994

• government of Flanders:o April 1995

• foundation by notarial deed:o July 1995

• operations:o January 1996

Reduction to practice (2)Partnership with universities

• university campus• empower univ staff with VIB staff• framework agreement VIB-univ• mutual added value• share return on investment

– Publications: 2 affiliations– IPR: joint IP (VIB in charge)

VIB today

VIB: Mission

To create groundbreaking knowledge on the molecular mechanisms ruling life for the benefit of scientific progress and the benefit of society

Excellence in science+

Excellence in tech transfer

VIB state of affairs

• multisite institute (JV with univ)• 1350 scientists – technicians (50/50)• 76 research groups• 8 departments• management agreement (2012-2016)

• 43.8 M€/year• 5 years• key performance indicators

Basic Research@VIBMolecular mechanisms

• molecular medecine– normal growth and development– health vs disease

neurobiology cancer inflammation cardiovascular

• molecular farming– normal growth and development– normal vs stress

Basic Research@VIB

• centre of excellence• important biological questions• stimulating environment

– VIB grant– research infrastructure– disruptive technologies– dialective environment– institutional integration

Science policyMaking the Difference

• frontline (not me too)• world class (international competition)• relevance + quality

good record of high impact publications and patent applications

performance

=

Results 2013

Results 2013

• 620 peer reviewed publications• 168 breaktrough articles (68 T1%)• 70 PhD’s

Publications in top journals (T5%)

'95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '130

20

40

60

80

100

120

140

160

180

Excellence in tech transfer

Path towards value creation

Agreements

Start-ups

IPR

An integrated and pro-active team

IP Management

Business Development New Ventures

License & BD deals

AssessmentTT Projects

Start-up Projects

Licensing case Start-up case

A proactive IP strategy

0

5

10

15

20

25

30

35

40

4595 96 97 98 99

2000 '0

1'0

2'0

3'0

4'0

5'0

6'0

7'0

8'0

9 10 11 12 13

non-VIB

VIB

• VIB patent estate: 218 patent families

116 partnering agreements signed

95 96 97 98 99 00 '01 '02 '03 '04 '05 '06 '07 '08 '09 10 11 12

VIB 0 8 8 15 15 34 29 47 65 61 69 59 82 80 94 111 124 116

0

20

40

60

80

100

120

140

VIB integrated approach towards start-ups

Evaluate technology & business opportunity

Build IPR platformPerform FTO analysis

Conceptualize and write business plan

Facilitate start-up and early stage

Search for managementRoad show to

investors

VIBPOC Fund

Seed Capital Fund

VIB start-ups: from knowledge to products

608 employees

8 M€

5 M€

5 M€

14.5 M€

20 M€

2 M€

2 M€

5 M€

+ 29 M€ => IPO => Tradesale

+ 25 M€ + 11 M€ => Tradesale

+ 25M€ + 40 M€ => IPO

+ 7.9 M€ + 5.1 M€

+ 15.5 M€ + 10.7M€

+ 5.5M€

VIB start-ups: equity investment and exit

• Total investment in VIB start-ups (€)

– VC/private : 255.200.000– IPO/PIPE/SPO : 272.500.000

527.700.000

~ 50% international

VIB start-ups: a magnet for foreign investments

Products: therapeutic pipeline

• 13 therapeutics under development, including 1 small compound

VIB as facilitator for the biotech sector

Infrastructure

Attracting/consolidatingcompanies to/in Flanders

Building networks

Bio-incubator Leuven

34

UGent Technology Park: Large Cluster in Biotechthe largest R&D hub in AgBio in Europe

DevGen

arGEN-X

Bayer Crop Science

(former PGS)

VIB/UGent

VIB BioincubatorActogenix, ADX Neuroscience,

Biomaric, BIP, Complix, Pronota, Seps Pharma, Yakult,

Q-Biologicals

Bioaccelerator I

Bioaccelerator II

Ablynx

InnogeneticsIIC Ugent

Oxyrane, Genohm,

Biogazelle, Feops, Com & Sciense, Quinvita, Bio-

ActorCropDesign

Anabiotec

Fytolab

1900 employees

Ghent Agrobiotech cluster

Ghent Biomed campus

From science to value

Policy factors impacting innovation: The case of FlandersJo Bury, managing director VIB

Science policy (2)Making the right Choices

• selecting on excellence• bottom up approach• strategic plan (15.10)• exposure to SABs• monitoring (w y m i w y g)• evaluation• reward excellence (rotation)• VIB grant allocation ~ performance